Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 16,489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Connective Tissue Disorder Clear all
Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 19, 2026, 2:20 AM EDT
Completed No phase listed Observational

miR-200b & miR-21 in Diabetic Wounds

NCT02581098
View directory record Official record
Conditions
Diabetes Mellitus, Foot Ulcer, Ulcer, Diabetic Foot Ulcer, Wound, Wound Heal
Interventions
No interventions
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated Not applicable Interventional

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06455475
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Derm-Maxx
Other
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Athens, Alabama • Encino, California • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Not applicable Interventional

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

NCT02957981
View directory record Official record
Conditions
Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Web-based Counseling, Standard Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 70 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

NCT00184067
View directory record Official record
Conditions
Melanoma
Interventions
Montanide ISA 51
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

NCT00482105
View directory record Official record
Conditions
Melanoma
Interventions
EGIR Tape
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

NCT00001705
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
GP100 peptide, IL-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated No phase listed Observational

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions
FNA Biopsy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

NCT02198651
View directory record Official record
Conditions
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca

NCT02453737
View directory record Official record
Conditions
Breast Cancer
Interventions
Brachytherapy APBI, 3D-CRT (photon) APBI, Proton APBI
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 2:20 AM EDT
Not listed Not applicable Interventional

Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes

NCT03041844
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Ulcer
Interventions
Low Frequency, Low Intensity Ultrasound, Sham Applicator
Device
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer

NCT00214864
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
docetaxel, capecitabine
Drug
Lead sponsor
Cancer Research Network
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 19, 2026, 2:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299
View directory record Official record
Conditions
Psoriasis
Interventions
VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

NCT00001193
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
high dose melphalan and autologous bone marrow transplantation
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

NCT03402893
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
ONEXTON Topical Gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 19, 2026, 2:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine

NCT00062465
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TwHF
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

NCT00782067
View directory record Official record
Conditions
Leukemia
Interventions
Midostaurin (PKC412)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 2:20 AM EDT